Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Assets (2019 - 2025)

Revolution Medicines has reported Current Assets over the past 7 years, most recently at $2.1 billion for Q4 2025.

  • Quarterly results put Current Assets at $2.1 billion for Q4 2025, down 10.85% from a year ago — trailing twelve months through Dec 2025 was $2.1 billion (down 10.85% YoY), and the annual figure for FY2025 was $2.1 billion, down 10.85%.
  • Current Assets for Q4 2025 was $2.1 billion at Revolution Medicines, up from $2.0 billion in the prior quarter.
  • Over the last five years, Current Assets for RVMD hit a ceiling of $2.3 billion in Q4 2024 and a floor of $483.0 million in Q2 2022.
  • Median Current Assets over the past 5 years was $922.4 million (2023), compared with a mean of $1.3 billion.
  • Biggest five-year swings in Current Assets: dropped 26.92% in 2022 and later soared 184.66% in 2023.
  • Revolution Medicines' Current Assets stood at $589.8 million in 2021, then grew by 11.94% to $660.2 million in 2022, then soared by 184.66% to $1.9 billion in 2023, then rose by 23.86% to $2.3 billion in 2024, then fell by 10.85% to $2.1 billion in 2025.
  • The last three reported values for Current Assets were $2.1 billion (Q4 2025), $2.0 billion (Q3 2025), and $2.2 billion (Q2 2025) per Business Quant data.